Skip to content

ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2013-05-15

What ELOXX PHARMACEUTICALS, INC. reported in its quarterly report filed 2013-05-15 (fiscal Q3 2013): 27 published measures, 85 facts as tagged in accession 0001144204-13-029119.

This filing

Form
10-Q (quarterly report)
Filed
2013-05-15
Fiscal period
fiscal Q3 2013
Accession
0001144204-13-029119 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-03-316,891,594USD
At 2012-06-306,954,869USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-03-313,580,106USD
At 2012-06-303,501,841USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-03-313,311,488USD
At 2012-06-303,453,028USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-03-311,581,037USD
At 2012-06-302,001,325USD
At 2012-03-313,207,251USD
At 2011-06-303,609,954USD
At 1998-06-300USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-836,583USD90
2012-07-01 to 2013-03-31-4,191,922USD274
1998-07-01 to 2013-03-31-61,128,676USD5388
2012-01-01 to 2012-03-31-1,060,659USD91
2011-07-01 to 2012-03-31-3,627,213USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-07-01 to 2013-03-31-2,956,298USD274
1998-07-01 to 2013-03-31-39,978,688USD5388
2011-07-01 to 2012-03-31-3,277,907USD275

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-07-01 to 2013-03-311,281USD274
1998-07-01 to 2013-03-31185,947USD5388
2011-07-01 to 2012-03-314,461USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-07-01 to 2013-03-312,930,955USD274
1998-07-01 to 2013-03-3148,364,048USD5388
2011-07-01 to 2012-03-313,218,879USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-07-01 to 2013-03-31-394,945USD274
1998-07-01 to 2013-03-31-6,804,323USD5388
2011-07-01 to 2012-03-31-343,675USD275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-03-315,200USD
At 2012-06-305,857USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-03-31202,174USD90
2012-07-01 to 2013-03-31552,303USD274
1998-07-01 to 2013-03-3112,658,256USD5388
2012-01-01 to 2012-03-31201,847USD91
2011-07-01 to 2012-03-31609,875USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-1,044,274USD90
2012-07-01 to 2013-03-31-3,590,474USD274
1998-07-01 to 2013-03-31-54,650,756USD5388
2012-01-01 to 2012-03-31-1,108,729USD91
2011-07-01 to 2012-03-31-3,845,012USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-03-313,293,540USD
At 2012-06-303,549,849USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-03-313,218,618USD
At 2012-06-303,163,317USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-03-31686,948USD
At 2012-06-30594,514USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-01-01 to 2013-03-31492,850USD90
2012-07-01 to 2013-03-311,597,362USD274
1998-07-01 to 2013-03-3122,832,967USD5388
2012-01-01 to 2012-03-31540,789USD91
2011-07-01 to 2012-03-311,926,492USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-03-31146,975,283shares
At 2012-06-3094,112,483shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-03-3174,272,233USD
At 2012-06-3069,952,152USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2013-03-313,587,683USD
At 2012-06-303,393,992USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-03-3199,728USD
At 2012-06-3099,728USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-03-31344,588USD
At 2012-06-30369,695USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-986,719USD90
2012-07-01 to 2013-03-31-4,990,213USD274
2012-01-01 to 2012-03-31-1,480,139USD91
2011-07-01 to 2012-03-31-5,083,153USD275

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-986,719USD90
2012-07-01 to 2013-03-31-4,990,213USD274
1998-07-01 to 2013-03-31-72,430,508USD5388
2012-01-01 to 2012-03-31-1,480,139USD91
2011-07-01 to 2012-03-31-5,083,153USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-31551,424USD90
2012-07-01 to 2013-03-311,993,112USD274
1998-07-01 to 2013-03-3133,607,789USD5388
2012-01-01 to 2012-03-31567,940USD91
2011-07-01 to 2012-03-312,118,520USD275

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2012-07-01 to 2013-03-31199,973USD274
2011-07-01 to 2012-03-31183,710USD275

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-01-01 to 2013-03-310USD90
2012-07-01 to 2013-03-310USD274
1998-07-01 to 2013-03-310USD5388
2012-01-01 to 2012-03-310USD91
2011-07-01 to 2012-03-310USD275

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-07-01 to 2013-03-3192,434USD274
1998-07-01 to 2013-03-31686,948USD5388
2011-07-01 to 2012-03-31245,256USD275

Inspect the source

Entity
ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
Captured
2026-09-20T05:15:09.498Z
SEC response SHA-256
b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))